NIBRT Management Teams

NIBRT Senior Leadership Team

Darrin

Darrin Morrissey

CEO

Darrin Morrissey, CEO, NIBRT Picture Conor McCabe Photography.

Darrin Morrissey - CEO

Darrin Morrissey was appointed CEO of NIBRT in June 2020. Immediately prior to joining, Darrin was the CEO at the Health Research Board (HRB), Ireland' primary funder of health and health system research. Previously Darrin was the Director of Programmes and Investments with Science Foundation Ireland (SFI), where he led the delivery of STEM research funding to the Irish research institutions. Darrin's past experiences also includes 16 years in the pharmaceutical industry - with GSK, Sanofi and others - in a variety of senior roles spanning across clinical research, commercial and manufacturing. Darrin qualified with a BSc in Microbiology and a PhD in Cancer Biology from University College Cork. Over recent years Darrin has been a member of numerous national and international policy and decision-making bodies, including the governing board of Science Europe, the British Irish Chamber of Commerce Higher Education & Research Steering Group, Knowledge Transfer Ireland Stakeholder Forum and Enterprise Ireland's Industrial Research and Commercialisation Committee.

NiallB Sized

Niall Barron

Principal Investigator

Niall-Barron

Niall Barron - CEO

Niall Barron was appointed NIBRT Principal Investigator and Professor of Biochemical Engineering in the School of Chemical and Bioprocess Engineering in UCD in 2017. He obtained a BA(Mod) in Microbiology from Trinity College Dublin and PhD in Applied Microbiology/Biochemistry from the University of Ulster in 1997. He spent three years at Baylor College of Medicine in Dr.Bert O'Malley's lab as a postdoctoral scientist working on genome engineering strategies to study nuclear steroid receptor function. He then returned to Ireland to work with Prof.Martin Clynes on stem cell engineering at the National Cell and Tissue Culture Centre in DCU. Subsequently, as a senior scientist in the National Institute for Cellular Biotechnology (NICB), he was instrumental in growing the mammalian cell engineering group with a specific focus on the production of recombinant therapeutic proteins.

Jonathan-Bones

Jonathan Bones

Principal Investigator

Jonathan-Bones

Jonathan Bones - Principal Investigator

Dr. Bones obtained his BSc in Analytical Science (Chemistry) and PhD in Analytical Chemistry from Dublin City University (DCU) under the guidance of Prof. Brett Paull. Following completion of his doctoral studies, Jonathan took a position at the Center for Bioanalytical Science in DCU, focused on the development and application of long monolithic silica columns for high efficiency LC-MS profiling of cell culture media, a collaboration with Bristol Myers Squibb

Gemma-Grimes

Gemma Grimes

HR Manager

Gemma-Grimes

Gemma Grimes - HR Manager

Gemma Grimes (MBS, MCIPD) joined the NIBRT team as HR Manager in October 2017. Gemma is an experienced HR professional with nearly 15 years' experience across many sectors and industries. A graduate of NUI Galway in HR and Industrial Relations, Gemma went on to work in a number of HR roles in sporting, charitable, publishing, arts and culture and most recently bio pharma organisations. Gemma also volunteers her HR expertise as a Board member in an Irish charity focusing on international aid and development.

John-Milne

John Milne

Training Director

John-Milne

John Milne - Training Director

John joined NIBRT in 2013 in the role of Training Director and his responsibilities include working with the training team who are responsible for delivering NIBRT training and education programmes to both industrial and education clients. Before he joined NIBRT John worked as a consultant, working with several clients in the biologics area to develop purification processes and ancillary quality documentation. John graduated from University College Dublin with a PhD in Biochemistry specialising in molecular enzymology. Following some additional academic research he moved to industry. He has over 25+ yrs experience in the purification processes for proteins and peptide products. Within the biopharmaceutical industry he has worked with Archport Ltd., and BioUetikon Ltd., both contract manufacturing organisations. In his role as Technical Manager in BioUetikon, he was responsible for technical operations. Throughout his career in industry he has performed in a variety of roles from process development, scale-up, tech transfer and GMP commercial production.

NIBRT

Killian O'Driscoll

Director of Projects

Killian-ODriscoll

Killian O'Driscoll - Director of Projects

Killian O'Driscoll is the Director of Projects at the National Institute for Bioprocessing Research and Training (NIBRT). Killian is a Genetics Graduate from Trinity College Dublin with an MSc in the Management of Innovation from the University of London. He also is an Associate Lecturer in Project Management at Dublin Business School. Prior to joining NIBRT, Killian worked with Microsoft European Operations Centre as Senior Global Project Manager and with Ericsson Competence Development Centre in the area of technology education and development. Killian working closely with all stakeholders in the biopharmaceutical industry has been involved in the successful establishment of NIBRT which has numerous international accolades including ISPE Facility of The Year, Bioprocess International Manufacturing Collaboration of the Decade and NIBRT is now recognized as a global leader in biopharma research and training.

Elizabeth-Topp

Elizabeth Topp

CSO

Elizabeth-Topp

Elizabeth Topp - CSO

Elizabeth Topp is the Chief Scientific Officer (CSO) at the National Institute for Bioprocessing Research & Training (NIBRT) and a professor in the College of Pharmacy at Purdue University. Topp is an acknowledged global leader in drug product manufacturing. Her research has focused on the chemical and physical stability of protein drugs, which she has patented through the Purdue Research Foundation Office of Technology Commercialization. Topp serves as a director for Purdue's LyoHUB, an industrial consortium to advance lyophilization technology.

NIBRT Board of Directors

Brendan REsized 2

Brendan O'Callaghan

Chair

Brendan O'Callaghan

Brendan O'Callaghan

Brendan is Executive Vice President, Global Industrial Affairs at Sanofi, an innovative global healthcare company.

In this role which sees him sit on Sanofi’s Executive Committee, he leads an international network of more than 70 manufacturing and distribution sites.

Brendan joined Sanofi in 2015 and was previously Global Head of Biologics and led Industrial Affairs Specialty Care. He has played a key role in supporting Sanofi’s transformation to a fully integrated biopharma company and in advancing digital transformation across the company’s manufacturing network.

Prior to Sanofi, Brendan worked at Schering-Plough before moving to Merck/MSD as Head of Biologics and later Vice President of its Europe, Middle East & Africa Operations.

Brendan graduated in chemical engineering from UCD, where he currently serves as an honorary adjunct Professor of Chemical and Biochemical Engineering.

Sarah

Prof. Sarah Culloty

Sarah Culloty

Prof. Sarah Culloty

Prof. Sarah Culloty is Head of the College of Science, Engineering and Food Science at University College Cork and has been Director of the Environmental Research Institute at UCC since 2014. As Head of College she leads a student and staff body of over 6000 with nine academic units and 24 affiliated research centres and institutes including the Environmental Research Institute, APC microbiome Ireland and the Tyndall National Institute. She holds a BSc and PhD in Zoology from UCC. She was Head of the School of Biological Earth and Environmental Sciences from 2014-2018. Sarah is a marine biologist and zoologist working on the impact of anthropogenic factors on the aquaculture and fisheries industry and more recently has been looking at the potential impact of climate change on these sectors. She has served on a number of national and international advisory boards and working groups and her research has informed international guidelines and legislation on aquatic animal health. She has had extensive engagement in supporting the EDI agenda at UCC and was part of the university’s committee when it received its first institutional Athena Swan award and was Head of one of the first schools at UCC to receive its award. She is currently a Governor of Fota Wildlife Park and chairs its Ethics Committee, is a board member of the Irish Aquaculture Technology and Innovation Platform and a member of the Ireland-United States Commission for Educational Exchange Board (t/a Fulbright Commission in Ireland).

Professor Orla Feely, Vice-President for Research, Innovation and Impact, University College Dublin.

Orla Feely

Professor Orla Feely, Vice-President for Research, Innovation and Impact, University College Dublin.

Orla Feely

Professor Feely is Vice President for Research, Innovation and Impact and a Professor of Electronic Engineering at University College Dublin. She holds a BE degree from University College Dublin and MS and PhD degrees fromthe University of California, Berkeley, where her PhD thesis won the DJ Sakrison Memorial Prize for outstanding and innovative research. While at UC Berkeley, she also won the Outstanding Graduate Student Instructor Award.

Her research is in the area of non linear circuits and systems, and she has been awarded research grants and prizes from a number of national, international and industry sources.

Professor Feely is a Member of the Royal Irish Academy and a Fellow of the IEEE (Institute of Electrical and Electronics Engineers), Engineers Ireland and the Irish Academy of Engineering. She has served as Chair of the Irish Research Council, the EU Advisory Group on Marie Sklodowska Curie Actions, and the IEEE Technical Committee on Non linear Circuits and Systems, and as a member of a number of Editorial Boards.

Professor Feely is Vice-President of Engineers Ireland and Vice-President for Resources and Treasurer of CESAER (the Conference of European Schools of Advanced Engineering Education and Research). She is a director of the Young Scientist and Technology Exhibition and Deputy Chair of the Higher Education Authority.

Norelee-Kennedy-square

Norelee Kennedy

Norelee-Kennedy-square

Norelee Kennedy

Prof Norelee Kennedy is Vice President Research and Associate Professor of Physiotherapy at the University of Limerick. She is a graduate of Trinity College Dublin (BSc Physiotherapy (1999); Postgraduate Diploma in Statistics(2000); PhD (2004).

In her role as Vice President Research Norelee has responsibility for the research affairs of the University and provides leadership in the formulation, development and delivery of the University's research strategy and policy and is a member of the University's Executive Committee.

Norelee leads a successful programme research in the field of rheumatology/physiotherapy. Currently she leads a Health Research Board funded project (DIFA scheme 2018) examining the feasibility of a physiotherapist led behaviour change intervention to promote physical activity in people with rheumatoid arthritis. She is the also UL lead on a large EU IMI funded project - IDEA-FAST - led by Prof Fai Ng, Newcastle University, examining digital end points for fatigue in inflammatory and neurodegenerative disorders.

Tom-Kelly-105-square

Tom Kelly

Tom-Kelly-105-square

Tom Kelly

Tom Kelly is Head of Enterprise Ireland's Innovation and Competitiveness Division and has responsibility for developing and implementing the organisation's strategy on Innovation and Operational Excellence. He is recognised as a "thought leader" on manufacturing and was a member of key Government Fora looking at the future of Manufacturing in Ireland.

Prior to taking up his current assignment he was Divisional Manager with responsibility for the Industrial and Lifesciences sectors and prior to that was senior manager within the Scaling Division, leading a team of specialists in business development and innovation management, working directly with a select group of fast growth clientfirms.

Awarded a PhD in Chemistry from University College Galway, for work on the catalytic properties of zeolites, he holds Masters Degrees in Materials Technology from the University of Sheffield and Industrial Engineering from University College Dublin. He is the author of several articles that have appeared in the scientific literature,spanning traditional and advanced ceramics as well as surface engineering technology.

Aine

Aine Hanly, Ph.D.

Aine Hanly, Ph.D.

Aine Hanly, Ph.D.

Aine Hanly, Ph.D., serves as Chief Technology Officer at Vir Biotechnology, where she is responsible for overseeing the Company’s technical operations. Her purview includes product and process development, supply chain, manufacturing, quality and CMC strategy for multi-modality products addressing the world’s most serious infectious diseases including COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. Aine’s career in the biomanufacturing industry, which has spanned roles in the UK, Ireland and the US, has been dedicated to advancing innovative solutions to accelerate commercialization and the delivery of medicines to patients.

Prior to joining Vir, Dr. Hanly served as the Vice President of Process Development for Amgen, accountable for clinical manufacturing and global supply of clinical trial materials. During her nearly decade-long tenure, she led teams enabling the commercialization of Amgen’s pipeline products as well as providing technical support for ongoing commercial manufacturing operations. Additionally, as site head at Amgen’s Cambridge facility, Dr. Hanly led the site’s transformation and staff growth, and together with the research and development team, greatly increased Amgen’s partnerships and presence within the local Cambridge ecosystem. She also worked for more than 10 years at Pfizer (formerly, Wyeth), where she held roles of increasing responsibility in analytical R&D, process development, quality and product supply strategy.

Dr. Hanly received her bachelor’s degree in biological chemistry and a Ph.D. in physical organic chemistry, from the University of Ulster, Northern Ireland. She completed her post-doctoral fellowship at Creighton University School of Medicine before joining the collaborative research wing at Yale University and CuraGen Corporation as lead scientist studying gene isolation and subsequent confirmation using a variety of molecular biology techniques.

Darrin Morrissey, CEO, NIBRT Picture Conor McCabe Photography.

Darrin Morrissey

Darrin Morrissey, CEO, NIBRT Picture Conor McCabe Photography.

Darrin Morrissey - CEO

Darrin Morrissey was appointed CEO of NIBRT in June 2020. Immediately prior to joining, Darrin was the CEO at the Health Research Board (HRB), Ireland' primary funder of health and health system research. Previously Darrin was the Director of Programmes and Investments with Science Foundation Ireland (SFI), where he led the delivery of STEM research funding to the Irish research institutions. Darrin's past experiences also includes 16 years in the pharmaceutical industry - with GSK, Sanofi and others - in a variety of senior roles spanning across clinical research, commercial and manufacturing. Darrin qualified with a BSc in Microbiology and a PhD in Cancer Biology from University College Cork. Over recent years Darrin has been a member of numerous national and international policy and decision-making bodies, including the governing board of Science Europe, the British Irish Chamber of Commerce Higher Education & Research Steering Group, Knowledge Transfer Ireland Stakeholder Forum and Enterprise Ireland's Industrial Research and Commercialisation Committee.

Tom Murray

Tom Murray

Robert_Baffi_Photo

Tom Murray

Tom Murray is a partner with Friel Stafford, one of Ireland’s leading business accounting and advisory firms. Tom qualified as a Chartered Certified Accountant (ACCA) in 1997. He is one of Ireland’s most experienced corporate recovery and turnaround practitioners and was one of the first Personal Insolvency Practitioners licensed in Ireland. He also is an experienced Corporate Financier with particular interest and expertise in the area of equity and debt fund raising, and the buying and selling of businesses. He has extensive experience of all areas of Litigation Support and Expert witness. He has worked with private clients, SMEs, national companies, multi-nationals, county councils and various Government and Regulatory agencies in defending and bringing proceedings. He is heavily involved with the ACCA accountancy body and is a past President of ACCA Ireland. He was nominated in January 2021 by ACCA to represent it on the the CCABI insolvency Committee. HE served on ACCA’s governing body, its global council, between 2013 and 2016. He is engaged by the three leading Accountancy bodies in Ireland as a lecturer for their CPD (Continuous Professional Development) in the area of Corporate Recovery, Corporte Finance and Personal Insolvency. Tom has written and presented two of the six modules in the Diploma in Insolvency run by Chartered Accountants Ireland and is a lecturer on its Diploma in Corporate Finance. He was asked to make numerous media appearance as an business advisor and has appeared on RTE’s main news bulletins, TV3, Sky News, Newstalk and Today FM for comments on insolvency issues and business matters. He is also a member of The Institute of Certified Public Accountants in Ireland, has a diploma in Forensic Accounting and is a Certified Mediator. He is authorised to act as a Personal Insolvency Practitioner by the Insolvency Service of Ireland

Julie-ONeil-square

Julie O'Neill

Julie-ONeil-square

Julie O'Neill

Julie O'Neill is a business professional with more than two decades of executive experience in senior leadership roles, Ms. O'Neill was formerly Executive Vice President, Global Operations at Alexion Pharmaceuticals, Inc. Prior to Alexion, she was Vice President of Operations at Gilead Sciences. Throughout her career in pharmaceutical operations, Ms. O'Neill has held a number of senior roles at the Board and Committee level. She is currently an Independent Director for at ICON plc, DBV Technologies SA, Achilles Therapeutics plc and ILC Dover LLC and is both a Board member and Audit & Risk Committee Chair for the National Institute for Bioprocessing Research & Training (NIBRT). Ms. O'Neill is a Chartered Director and holds a BSc in Pharmacy from Trinity College Dublin and an MBA from University College Dublin.

mike

Dr. Michael P. Thien

mike

Michael Thien

Until very recently, Mike started and has led the Manufacturing Systems Design and Commercialization group at Merck & Co. Inc., a group responsible for developing the processes and methods for new products, new product technology transfer, deep scientific and engineering support for in-line products, new facility introduction and start-up, and development of the next & best practices for new facilities. Mike has worked in new product and process development, manufacturing operations and facility design and start-up at Merck for almost 30 years. After receiving his B.S. in Chemical Engineering from Caltech (1982) and Sc.D. from MIT in biochemical engineering (1988), Mike joined the Merck Research Labs, working in vaccines and recombinant proteins. Mike was process development leader and plant start-up leader for the first effective commercial HIV protease inhibitor, CRIXIVAN (for which he was given his division’s top recognition), made key contributions to Merck’s JANUVIA (a treatment for Type II diabetes) and led the design of Merck’s commercial supply chain for KEYTRUDA (an immune-oncology agent). In October, Mike took on a new role consulting on reimagining talent systems for Merck’s Global Talent Management area. Mike has received awards from the American Institute of Chemical Engineers, the US Manufacturing Leadership Council and the American Chemical Society. He has served on Advisory Committees for the Chemical Engineering Departments at MIT, U. Texas at Austin, Johns Hopkins and Tufts University (where he served as chair) and is a trustee for the Robert Wood Johnson University Hospital at Rahway, New Jersey USA and on the University of Delaware Board of Bio-Innovation. In 2019-2021, he represented the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) to the International COVAX Manufacturing Sub-team for COVID-19 Vaccines. Most recently, he joined the Board of Ireland’s National Institute of Bioprocessing Research and Training (NIBRT)

AMH 2021 Headshot (2)

Anne Marie Healy

AMH 2021 Headshot (2)

Anne Marie Healy

Anne Marie Healy is Professor of Pharmaceutics and Pharmaceutical Technology in the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin. Anne Marie has a B.Sc. in Pharmacy and a Ph.D. in Pharmaceutics, both from the University of Dublin. She joined the School of Pharmacy, TCD in 1992 as a Lecturer in Pharmaceutics. In 2010 she was elected Fellow of Trinity College.

Anne Marie has held a number of senior administrative positions in Trinity College, including Director of Undergraduate Teaching and Learning in the School of Pharmacy and Pharmaceutical Sciences (2008-2012) and Head of School (2013-2019). She has acted as external examiner at the Master and PhD level in Ireland and abroad, and has served on a number of external bodies and boards, such as the Board of the Irish Platform for Patient Organisations, Science and Industry and the Council of the Pharmaceutical Society of Ireland, as well as acting as a consultant to a number of pharmaceutical companies in Ireland and the US.

Anne Marie has published extensively; her research interests include pharmaceutical material science, preformulation and formulation of pharmaceuticals, amorphous solids, co-crystals, formulating poorly soluble drugs, pharmaceutical processing and pulmonary drug delivery. She is a Co-Principal Investigator of the SSPC - the Science Foundation Ireland Research Centre for Pharmaceuticals (www.sspc.ie) and is one of the Co-Directors of the EPSRC-SFI Centre for Doctoral Training in Transformative Pharmaceutical Technologies (https://www.transpharmtech-dtc.ac.uk/).

NIBRT Science Advisory Board Members

pas

Parviz Ayazi-Shamlou

Robert_Baffi_Photo

Parviz Shamlou

Parviz Shamlou is the Founding Vice President and Executive Director at Jefferson Institute for Bioprocessing (JIB) at Thomas Jefferson University (TJU). Parviz is a chemical engineer with over 35 years of experience in transitioning innovative technologies and solutions from ideation to market, much of it focused in the areas of biopharmaceutical and biologics. He has worked both in industry and academia leading and managing multidisciplinary teams of scientists and engineers in process design, scale-up, technology transfer and manufacturing of clinical and licensed biopharmaceutical products including monoclonal antibodies, fusion proteins, and PEGylated proteins, amongst other. His scientific expertise include bioprocessing of protein replacement therapeutics as well as emerging medicine including cell and gene therapy and advanced vaccines. His technical knowledge expands across upstream and downstream operations process scale up and modelling, process intensification, continuous bioprocessing, and process analytical technology. He has led and managed several process development facilities and projects from ground up. Currently, his responsibilities include a multi-million dollar expansion of the TJU’s bioprocessing capability at JIB. The planned expansion includes approx. 10,000ft2 of clinical grade (Phase I/II) cGMP facility intended to support TJU’s translational research in cell and gene therapy and modern vaccines as well as nearly 25,000ft2 of pilot and lab areas dedicated to process development, training and workforce development. Prior to Thomas Jefferson University, Parviz held a variety of scientific and leadership roles in industry and academia, including 20 years at University College London (UCL), in UK, 5 years at Keck Graduate Institute (KGI) in Claremont, CA and 11 years at Eli Lilly and Company in Indianapolis, Indiana where he led early and late phase development of clinical manufacture for over a dozen biologics two of which reached successful market launch. He has supervised and acted as co-supervisor of over 25 PhD and postdoctoral researchers in industry and academia and has published over 200 papers, articles, reports and books in bioprocessing.

Robert_Baffi_Photo-square

Robert Baffi

Robert_Baffi_Photo-square

Robert Baffi

Robert A. Baffi, Ph.D., has proven leadership skills in biotechnology with a product development emphasis. He had a 20-year tenure at BioMarin and as President of Global Manufacturing & Technical Operations was responsible for overseeing manufacturing, process development, quality, logistics, engineering and analytical chemistry. Dr. Baffi served 14 years in a number of increasingly responsible positions at Genentech, Inc., primarily in the functional area of quality control. Prior to Genentech, Dr. Baffi worked for Cooper BioMedical as a Research Scientist and at the Becton Dickinson Research Center as a Post-Doctoral Fellow. Dr. Baffi has contributed to the approval and commercial success of 28 products. He serves on the board for the National Institute for Bioprocessing Research & Training and Neurogene Inc. Dr. Baffi received a Ph.D., M. Phil. and a B.S. in biochemistry from the City University of New York and an M.B.A. from Regis University.

Martin-Clynes-square

Martin Clynes

Martin-Clynes-square

Martin Clynes

Martin Clynes is part of team that designed Ireland's first Biotechnology B.Sc., including Process Engineering as well as Biology at DCU (then NIHE Dublin) - first graduates in 1986.Founding Director of Ireland's National Cell and Tissue Culture Centre (1987) and National Institute for Cellular Biotechnology (NICB - building opened 2006). Research interests in cell culture technology (many industry collaborations and founded animal cell - based biopharmaceutical contract manufacturing company on DCU campus, Archport Ltd, later sold by DCU to CPH and became Biouetikon ) ;and (closely collaborating with clinical colleagues) in translational cancer, diabetes and ocular research. Also interested in Bioethics. Part of team that brought corneal stem cell therapy into clinical use in Ireland. Supervised or co-supervised more than 80 Ph. D. students to graduation, and was co-recipient of Nature's 2014 lifetime award for scientific mentorship. Currently Emeritus Professor of Biotechnology at DCU.

Charles-L.-Cooney-square

Charles L. Cooney

Charles-L.-Cooney-square

Charles L. Cooney

Charles L. Cooney is the Robert T. Haslam (1911) Professor of Chemical and Biochemical Engineering, Emeritus in the Department of Chemical Engineering at MIT and founding Faculty Director, Emeritus of the Deshpande Center for Technological Innovation. His academic career has focused on biotech and pharma process design, operation, economics and control; continuous processing has been a reoccurring theme throughout his research. He has been involved as founder, advisor or board member of over 25 companies and currently sits on the Boards of Directors of Codiak Bioscience, Innovent Biologics (1801.HK), Elektrofi, Iterative Scopes, Levitronix Technologies, LayerBio, Boyd Technologies and is chairman of GreenLight Bioscience. In addition, he is Trustee Emeritus of Boston Ballet, Advisor Emeritus of the Boston Symphony Orchestra and Trustee of the Leventhal Map and Education Center. Other interests include: high altitude mountaineering (assents of Denali, Ama Dablam, Mont Blanc, Kilimanjaro, Huascaran) and antique map collecting.

Matt-Croughan-square

Matt Croughan

Charles-L.-Cooney-square

Matt Croughan

Matt Croughan, Ph.D., Biotechnology Industry Consultant and Co-Founder, Claymore Bio LLC. For 23 years, Matt has worked as an independent consultant in bioprocess development and manufacturing with more than 95 clients. From 2013 to 2014, he was also the Chief Technology Officer at Sapphire Energy, where he led the effort to economically produce renewable crude oil from algae. From 2006 to 2013, Matt served as the founding Rathmann Professor and Director of the Amgen Bioprocessing Center at KGI in Claremont, CA, with over 108 Masters and Doctoral graduates in bioprocessing. From 1988 to 1998, Matt worked at Genentech, where he developed the first high density, fed batch animal cell culture process, licensed for Pulmozyme in 1993. Just recently, Matt co-founded Claymore Bio LLC, to develop new therapies for infectious diseases, and published the book: COVID-19, A Guide to Home Health Care. Matt has two chemical engineering degrees, a Ph.D. from MIT (1988) and BS from UC Berkeley (1983).

gd

Gavin Davey

Alan-Dickson-1

Alan Dickson

Brian-Glennon-square

Brian Glennon

Brian-Glennon-square

Brian Glennon

Professor Brian Glennon is Professor of Chemical and Bioprocess Engineering in University College Dublin. He is also co-founder and Chief Technology Officer at APC Ltd, an Irish pharmaceutical research and development company. His research focus is on the application of process engineering strategies to the design and optimisation of manufacturing processes for biopharmaceuticals.

2020headshot

Brendan Hughes

2020headshot

Barry L. Karger

Brendan Hughes Ph.D is Senior Vice President for Global Manufacturing Operations at Bristol Myers Squibb, based in the US. Brendan is responsible for the manufacture of BMS biologics and pharmaceutical products across a worldwide network of internal and external plants. Brendan has spent 30 years in the biopharma industry leading teams in Process Development, Quality, MS&T and Manufacturing and has worked in the UK, US and Ireland. Brendan was a member of the drafting team for several of the initial ICH Guidance for Biopharma products which set the global standards for the CMC content of regulatory filings for these products. Brendan received his B.Sc and Ph.D in Biochemistry from NUI Galway and carried out post-doctoral research at the Institute of Virology in Oxford UK. .

Barry-L.-Karger-square

Barry L. Karger

Barry-L.-Karger-square

Barry L. Karger

Barry L. Karger is the Emeritus James L. Waters Chair in Analytical Chemistry and Distinguished Professor. He was the Founding and now Emeritus Director of the Barnett Institute of Chemical and Biological Analysis at Northeastern University. He has been an active researcher with 375 publications and 50 patents in the field of bioanalytical chemistry. Dr. Karger has received many honors including three American Chemical Society awards, the Bergman Medal from the Swedish Chemical Society, the Herovsky Gold Medal from the Czech Academy of Sciences, the Beckman Medal, and is an external member of the Hungarian Academy of Sciences. He has been a major contributor to the development of HPLC, and his technology in capillary electrophoresis played a significant role in the Human Genome Project. More recently he was involved in the development of new technologies for proteomics, especially trace level LC/MS analysis of proteins in biological matrices, and comprehensive characterization of complex biopharmaceuticals. He has co-founded several companies and actively collaborated with others in the biotechnology industry, especially in the characterization of biopharmaceuticals and the biology of production cell lines.

Barry-McCarthy-square

Barry McCarthy

Barry-McCarthy-square

Barry McCarthy

Barry is Snr Director with Janssen BioProcess Development, with responsibilities for Drug Substance Process Development within the Janssen Network in US, Ireland and the Netherlands. Barry joined Janssen in 2006. Prior to that he worked with Schering Plough ( now MSD) and Jacobs Engineering.

Pauline-Rudd-square

Pauline Rudd

Pauline-Rudd-square

Pauline Rudd

Prof. Pauline M. Rudd BSc, LRIC, MA (Oxon), FISSR, PhD is an Emeritus Fellow of the Conway Institute University College Dublin and Visiting Investigator at the Bioprocessing Technology Institute, AStar, Singapore. From 2006-2018 she was NIBRT Professor of Glycoproteomics and Glycobiology at University College, Dublin heading the NIBRT GlycoScience Group. She obtained a BSc in Chemistry at the University of London and a PhD in Glycobiology at the Open University, UK. She was a Founding Scientist of Wessex Biochemicals (later Sigma London) and after a long career break to raise 4 children, a member of the Oxford Glycobiology Institute for 25 years where she became a University Reader. She was a visiting scientist at The Scripps Research Institute, CA, Shanghai Medical University PRC, Ben Gurion University of the Negev, Israel and an Erskine Visiting Fellow, Canterbury University, Christchurch, New Zealand. She is a Fellow of the Royal Society of Medicine, London and a Visiting Professor at St. George's Hospital, London and an Adjunct Professor at North Eastern University, Boston, Trinity College, School of Medicine, University College Dublin, and NUIG Galway, Emeritus Fellow, Conway Institute, University College Dublin. Prof Rudd has >400 scientific publications and has given > 400 talks at international meetings. In 2010 PMR was awarded the James Gregory Medal at St. Andrews University and an Agilent Thought Leader award, in 2012 she received a Waters Global Innovation Award in NIBRT and in 2017 in BTI AStar Singapore. She received an Honorary Doctorate at the Sahlgrenska Institute, Univ. of Gothenburg (2015), the International Glycoconjugate Organisation Award for contributions to GlycoScience (South Korea 2017) and in 2019 she received the Karger Award for contributions to GlycoScience Analytical Technologies at Northeastern University, Boston.

Richard-Snyder-square

Richard Snyder

Richard-Snyder-square

Richard Snyder

Richard Snyder, Ph.D. is the Vice President for Science and Technology, Pharma Services at Thermo Fisher Scientific. He leads the S&T Team's companywide initiative developing multi-generational manufacturing and analytical platforms used for the GMP production of viral vectors utilized in in vivo human gene therapies and ex vivo modified-cell based therapies, designed to enable large pharma and biotech clients to accelerate the delivery of novel medicines to improve patients' health. Dr. Snyder has been investigating virus biology, vector development, cGMP vector manufacturing and analytical technologies, and viral vector-mediated gene transfer for over 34 years, and was a member of teams who developed novel viral vector-based human gene therapies. Dr. Snyder was an Associate Professor of Molecular Genetics and Microbiology, and Director of Biotherapeutic Programs at the University of Florida; an Assistant Professor of Pediatrics at Harvard Medical School; and was previously employed by Cell Genesys, Somatix, Merlin, and Avigen where he was engaged in the development of gene transfer vector and vaccine technology, along with therapeutic applications. Dr. Snyder has authored over 70 scientific publications and 8 US patents.

Alan-Dickson-1

Alan Dickson, PhD

Alan-Dickson-1

Alan Dickson, PhD

Alan is a Professor of Biotechnology at the University of Manchester and has primary research interests in the industrial applications of mammalian cells as factories for the production of therapeutic recombinant proteins and viral vectors. Alan directs of the Manchester Centre of Excellence in Biopharmaceuticals and is part of the organisational group for BioProNET2, both of which promote collaborations at the industrial/academic interface.